Intraneoplastic inoculation of dvB7Ig/G207 in the neuroblastoma syngeneic mouse model inhibited the cancer progression and substantially increased CD4+ and CD8+ T cell infiltration, and the mice cured by dvB7Ig/G207 treatment were protected against tumor rechallenge (85). Here, CD4 is linked to neoplasm.